<DOC>
	<DOCNO>NCT00342849</DOCNO>
	<brief_summary>The Treatment Lead-Exposed Children ( TLC ) clinical trial compare effect lead chelation succimer placebo therapy . TLC randomize , double-blind , placebo-controlled clinical trial site Cincinnati Columbus , Ohio , Philadelphia , Pennsylvania , Baltimore , Maryland Newark , New Jersey . The study design test outcome IQ , neuropsychological function , behavior , physical growth blood pressure three year initiation treatment . Enrollment conduct 1994 1997 , completion initial three-year follow-up 2000 .</brief_summary>
	<brief_title>Treatment Lead-Exposed Children Trial</brief_title>
	<detailed_description>At TLC enrollment , child 12 33 month age baseline blood lead level ( PbB ) 20 44 microg/dl . Of 1,854 referred child screen eligibility , 780 randomize active drug ( oral succimer ) placebo group , stratify clinical center , body surface area , blood lead level language speak home ; New Jersey Clinical Center enrol Spanish-speaking participant . Up three 26-day course succimer placebo therapy administer depend response treatment give active drug . Eighty-nine percent child finish treatment six month , child finish 13 month randomization . Residential lead clean-up nutritional supplementation multivitamin mineral provide study child , irrespective treatment group . Children follow three year , regular physical exam , psychological developmental testing , measurement lead concentration venous blood . Treatment follow close trial ; open scientific analysis report write . Although succimer lower blood lead level much effectively placebo , difference two group psychological test three year post randomization , child five year old . Follow TLC child continue school age . At age seven , 647 780 subject remain study . Children test age seven seven half standardized neuropsychological battery tap cognition , behavior , learn memory , attention , neuromotor skill . While chelation therapy succimer lower average blood lead level approximately six month , result benefit cognitive , behavioral neuromotor endpoint measure school age child . These additional follow-up data confirm previous find TLC regimen chelation therapy associate neurodevelopmental benefit child blood lead level 20 44 microg/dL .</detailed_description>
	<mesh_term>Succimer</mesh_term>
	<criteria>INCLUSION CRITERIA : The study population reflect population know great risk lead exposure , i.e. , low income , urban , AfricanAmerican child . EXCLUSION CRITERIA : Linguistic minority exclude center except Newark , Hispanic child make sizable portion population include .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>33 Months</maximum_age>
	<verification_date>June 10, 2015</verification_date>
	<keyword>Clinical Trial</keyword>
	<keyword>Low-level Lead Poisoning</keyword>
	<keyword>Chelation</keyword>
	<keyword>Developmental Assessment</keyword>
	<keyword>Succimer</keyword>
</DOC>